Changxing County People's Hospital
Conditions
Interventions
Control group:Take the drug Ebastine.
Treatment Group 1:Taking Ebastine and Du Mai moxibustion treatment
Treatment Group 2:The combination of ebastine and Du Meridian moxibustion treatment group
Sponsors
Changxing County People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: 1) Patients met the diagnostic criteria for chronic urticaria in traditional Chinese medicine and Western medicine and all patients were clinically diagnosed; 2) The course of disease exceeded 6 weeks with more than three episodes per week or one episode every two days and the duration was less than 24 hours; 3) Ages greater than 18 and less than 60. no immunosuppressants glucocorticoids or other drugs affecting T lymphocyte subsets and coagulation function had been taken in the past 4 weeks; 4) None of them had a history of allergy or contraindications to moxibustion on the Governor Vessel in traditional Chinese medicine or ebastine and all patients could tolerate it.
Exclusion criteria
Exclusion criteria: Exclusion Criteria: 1) Individuals with psychiatric disorders, cognitive dysfunction, or blood system diseases; 2) Those with severe liver or kidney dysfunction, primary hematopoietic disorders, or autoimmune diseases; 3) Pregnant women, nursing mothers, or individuals with poor adherence to treatment; 4) Individuals with psychiatric disorders, concurrent skin infections, or other types of urticaria; 5) Patients with severe gastrointestinal symptoms, organic diseases, or other allergic diseases. Termination of the Trial Criteria: 1) Patients who do not adhere to the treatment regimen or cannot receive treatment on time, or those receiving additional treatments; 2) Patients lost to follow-up or whose data are incomplete, affecting the assessment of treatment efficacy; 3) Patients experiencing severe drug side effects or adverse reactions (e.g., skin allergies); 4) Patients who experience clinical adverse events during the trial; 5) Patients who develop other complications or whose condition worsens and cannot continue conservative treatment according to this protocol; 6) Patients who withdraw from the trial in the middle; 7) Patients whose condition worsens and cannot continue conservative treatment according to this protocol; 8) Patients who change their treatment method in the middle, making it impossible to determine efficacy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Symptom Score;Inflammatory factors;Hemorheology;Quality of Life Assessment Form (SF-36); | — |
Countries
china
Contacts
Public Contactmengdi she
Changxing County People's Hospital
Outcome results
None listed